In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point

International Journal of Antimicrobial Agents

Volumn 25, Issue 2, 2005, Pages 163-167

  Alkorta, M ^a   Gimenez M J ^b   Vicente, D ^a   Aguilar, L ^b   Perez Trallero E ^a  

^a HOSPITAL DONOSTIA   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

Gemifloxacin; Levofloxacin; Mouse model; Moxifloxacin; S. pneumoniae

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC;

ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOCOMPETENCE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; POINT MUTATION; QUINOLINES; SEPSIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 12344255052     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.08.017     Document Type: Article

References (19)

1. E. Perez-Trallero, C. Fernandez-Mazarrasa, and C. Garcia-Rey Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain Antimicrob Agents Chemother 45 2001 3334 3340
2. F. Fuentes, M.J. Gimenez, F. Marco, L. Alou, L. Aguilar, and J. Prieto In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin Eur J Clin Microbiol Infect Dis 19 2000 137 139
3. E. Perez-Trallero, J. Larruskain, J.M. Marimon, I. Ayestaran, and J.M. Garcia Arenzana In vitro activities of 10 fluoroquinolones against clinical isolates of Streptococcus pneumoniae during 1999 and 2000 in Gipuzkoa, Spain Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington DC, USA, Chicago, IL, USA 2001 180
4. P. Joyanes, A. Pascual, M.J. Gimenez, I. Garcia, L. Aguilar, and E. Perea Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae Chemotherapy 47 2001 409 414
5. J. Prieto, L. Aguilar, and F. Fuentes Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers Int J Antimicrob Agents 18 2001 231 238
6. M. Garcia-Olmos, A. Parra, and G. Garcia-Calvo Efficacy and pharmacodynamics of a human like gemifloxacin versus levofloxacin treatments on guinea pigs experimental pneumonia induced by Streptococcus pneumoniae strains with decreased ciprofloxacin susceptibilities Int J Antimicrob Agents 21 2003 568 573
7. NCCLS Performance standards for antimicrobial susceptibility testing - 12th Informational Supplement, M100-S12 2002 National Committee for Clinical Laboratory Standards Villanova, PA
8. M. Kim, and C.H. Nightingale Pharmacokinetics and pharmacodynamics of the fluoroquinolones V.T. Andriole The quinolones 3rd ed. 2000 Academic Press London 169 202
9. E. Perez-Trallero, J.M. Garcia-Arenzana, J.A. Jimenez, and A. Peris Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin Eur J Clin Microbiol Infect Dis 9 1990 905 906
10. P.E. Empey, H.R. Jennings, A.C. Thornton, R.P. Rapp, and M.E. Evans Levofloxacin failure in a patient with pneumococcal pneumonia Ann Pharmacother 35 2001 687 690
11. R. Davidson, R. Calvacanti, and J.L. Brunton Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 346 2002 747 750
12. X.S. Pan, J. Ambler, S. Mehtar, and L.M. Fisher Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob Agents Chemother 40 1996 2321 2326
13. NCCLS Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved Standard M7-A4 1997 National Committee for Clinical Laboratory Standards Villanova, PA
14. NCCLS Methods for determining bactericidal activity for antimicrobial agents, Document M26-T 1992 National Committee of Clinical Laboratory Standards Villanova, PA
15. European Community. Journal officiel des communautés européennes, 18 décembre. Report L358. Luxembourg: Office des publications officielles des communautés européennes; 1986.
16. F. Garcia-Garrote, E. Cercenado, J. Martin-Pedroviejo, O. Cuevas, and E. Bouza Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens J Antimicrob Chemother 47 2001 681 684
17. V. Lorian Medical relevance of low concentrations of antibiotics J Antimicrob Chemother 31 Suppl D 1993 137 148
18. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10 [quiz 11-2]
19. D. Croisier, P. Chavanet, and C. Lequeu Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones J Antimicrob Chemother 50 2002 349 360